A Phase Ib Study of Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain

Trial Profile

A Phase Ib Study of Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain

Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Oxcarbazepine (Primary) ; Morphine
  • Indications Cancer pain
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Aug 2016 Status changed from recruiting to discontinued due to poor accrual.
    • 11 Dec 2014 Planned End Date changed from 1 Jan 2015 to 1 Jan 2017 as reported by ClinicalTrials.gov.
    • 21 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top